



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BAY-1436032

Item No. 35709

CAS Registry No.: 1803274-65-8
Formal Name: 2-[[4-(trifluoromethoxy)phenyl]amino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]-1H-benzimidazole-5-propanoic acid
MF: C₂₆H₃₀F₃N₃O₃
FW: 489.5
Purity: ≥98%
UV/Vis.: λ_{max}: 295 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAY-1436032 is supplied as a solid. A stock solution may be made by dissolving the BAY-1436032 in the solvent of choice, which should be purged with an inert gas. BAY-1436032 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of BAY-1436032 in DMF is approximately 1 mg/ml and approximately 3 mg/ml in ethanol and DMSO.

Description

BAY-1436032 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1; IC₅₀ = 0.015 μM for both IDH1^{R132H} and IDH1^{R132C}).¹ It is selective for mutant IDH1 over wild-type IDH1 and IDH2 (IC₅₀s = 20 and >100 μM, respectively). BAY-1436032 inhibits production of α-hydroxyglutaric acid (2-HG; Item Nos. 25894 | 16374) in HEK293 cells expressing IDH1^{R132H}, IDH1^{R132C}, IDH1^{R132G}, IDH1^{R132S}, and IDH1^{R132L}, but not IDH1^{R100Q}, IDH2^{R172K}, IDH2^{R172W}, or IDH2^{R172M}. It also inhibits 2-HG production in LN-229 glioblastoma and HCT116 colorectal carcinoma cells overexpressing IDH1^{R132H} (IC₅₀s = 73 and 47 nM, respectively), as well as in HT-1080 sarcoma cells endogenously expressing IDH1^{R132C} (IC₅₀ = 135 nM). BAY-1436032 (150 mg/kg) reduces tumor growth and increases survival in an NCH551b IDH1^{R132H} mutant secondary glioblastoma patient-derived xenograft (PDX) mouse model. It also induces myeloid differentiation of IDH1^{R132C} mutant acute myeloid leukemia (AML) cells in mice when administered at doses of 45 and 150 mg/kg.²

References

1. Pusch, S., Krausert, S., Fischer, V., *et al.* Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. *Acta Neuropathol.* **133(4)**, 629-644 (2017).
2. Chaturvedi, A., Herbst, L., Pusch, S., *et al.* Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. *Leukemia* **31(10)**, 2020-2028 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM